Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Arcus Biosciences Inc RCUS

Healthcare Biotechnology
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab,... see more

Recent & Breaking News (NYSE:RCUS)

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire 2 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire March 24, 2026

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire March 9, 2026

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Business Wire February 26, 2026

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Business Wire February 25, 2026

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Business Wire February 23, 2026

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

Business Wire February 11, 2026

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire January 26, 2026

Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs

Business Wire January 7, 2026

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Business Wire December 18, 2025

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Business Wire December 12, 2025

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire December 9, 2025

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Business Wire November 18, 2025

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Business Wire October 30, 2025

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Business Wire October 30, 2025

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Business Wire October 28, 2025

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Business Wire October 19, 2025

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Business Wire October 12, 2025

Arcus Biosciences Announces New Employment Inducement Grants

Business Wire October 9, 2025

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Business Wire October 6, 2025

Podcasts